China-based chimeric antigen receptor (CAR) T cell therapy specialist, Legend Biotech Corporation (NASDAQ: LEGN), has announced the appointment of Alan Bash as the President of Carvykti, a BCMA-targeted chimeric antigen receptor T cell (CAR-T) therapy. In this role, Mr. Bash will oversee the continued growth of Carvykti, managing Legend Biotech’s commercial, technical operations, and quality functions for the franchise.
Alan Bash’s Extensive Background in Oncology and Biotech
Mr. Bash brings a wealth of experience to Legend Biotech, having served as Chief Executive Officer for two oncology-focused biotech companies, most recently at ZielBio. Prior to that, he held the position of President and CEO at Checkmate Pharmaceuticals. His career includes a 23-year tenure at Bristol Myers Squibb (BMS, NYSE: BMY), where he held various leadership roles across all major therapeutic areas, including oncology. During his time there, he played a pivotal role in the U.S. launch of Opdivo and the expansion of additional cancer treatments such as Yervoy and Erbitux. Mr. Bash also contributed to several blockbuster products in collaboration with other companies, including Abilify with Otsuka and Eliquis with Pfizer.- Flcube.com
